Benefits and Risks of Neoadjuvant Therapy for Liver Metastases
- 1 November 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (31) , 4954-4955
- https://doi.org/10.1200/jco.2006.07.9244
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver MetastasesJournal of Clinical Oncology, 2006
- Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal MetastasesJournal of Clinical Oncology, 2006
- Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver MetastasesAnnals of Surgery, 2006
- Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary NoteJournal of Clinical Oncology, 2005
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJournal of Surgical Oncology, 2005
- Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983Journal of Clinical Oncology, 2005
- Effect of Steatohepatitis Associated with Irinotecan or Oxaliplatin Pretreatment on Resectability of Hepatic Colorectal MetastasesJournal of the American College of Surgeons, 2005
- Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerAnnals of Oncology, 2004
- Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapyJournal of Gastrointestinal Surgery, 2003
- Impact of steatosis on perioperative outcome following hepatic resectionJournal of Gastrointestinal Surgery, 2003